Amylyx

In: Finance

spawns Amylyx Pharmaceuticals (NASDAQ:AMLX) traded sharply higher on Wednesday after the drug developer announced the acquisition of avexitide, a GLP-1 receptor antagonist developed by Eiger BioPharmaceuticals (OTC:EIGRQ). The transaction was completed on July 9 after Amylyx (AMLX) emerged as the winning bidder in an auction held to sell Avexitide underContinue Reading

In: Finance

phototechno Amylyx Pharmaceuticals (NASDAQ:AMLX) has signed an agreement with Eiger BioPharmaceuticals (OTC:EIGRQ) to acquire the rights to the latter’s Phase 3-ready GLP-1 receptor antagonist, Avexitide. Cambridge, Massachusetts-based Amylyx (AMLX) has agreed to pay $35.1M plus other payments for the acquisition, the company announced in an SEC filing late Friday. TheContinue Reading